Skip Navigation LinksHome > May 2012 - Volume 18 - Issue 5 > Antitumor necrosis factor treatment for pediatric inflammato...
Text sizing:
A
A
A
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.21871
Clinical Reviews

Antitumor necrosis factor treatment for pediatric inflammatory bowel disease

de Bie, Charlotte I. MD1; Escher, Johanna C. MD, PhD1; de Ridder, Lissy MD, PhD1,*

Collapse Box

Abstract

Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis factor‐α (TNFα), a proinflammatory cytokine with an increased expression in the inflamed tissues of inflammatory bowel disease (IBD) patients. Currently, infliximab is the only anti‐TNF drug that has been approved for use in refractory pediatric Crohn's disease (CD). Nevertheless, adalimumab and certolizumab have been used off‐label to treat refractory pediatric IBD. Over the past 10 years, anti‐TNF treatment has been of great benefit to many pediatric IBD patients, but their use is not without risks (infections, autoimmune diseases, malignancies). Despite the growing experience with these drugs in children with IBD, optimal treatment strategies still need to be determined. The purpose of this review is to summarize the current knowledge on the use of anti‐TNF drugs in pediatric IBD and to discuss the yet‐unsolved issues. (Inflamm Bowel Dis 2011;)

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.